Quantcast

Latest ENGLEWOOD Stories

2014-09-15 16:28:19

ENGLEWOOD, Colo., Sept. 15, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that its September 20, 2014 annual meeting of shareholders will be shared live through a webcast. This webcast will provide audio throughout supplemented by video of the slides and videos...

2014-09-12 04:21:05

Visit EchoStar at IBC RAI Hall 1, Stand F76 ENGLEWOOD, Colo., Sept. 12, 2014 /PRNewswire/ -- EchoStar Corporation, (NASDAQ: SATS), a premier global provider of satellite operations and video delivery solutions, will provide IBC attendees a sneak peek of its exciting new product for secure home automation during IBC in Amsterdam. http://photos.prnewswire.com/prnvar/20140728/130640 EchoStar, the award-winning creator of such popular consumer products as the Slingbox®, which allows...

2014-09-08 12:29:22

PCAB accreditation recognizes Brown's commitment to high quality control, quality assurance and quality improvement standards; assures patients receive high-quality medication. ENGLEWOOD, Colo., Sept. 8, 2014 /PRNewswire/ -- Brown's Compounding Center, a Colorado pharmacy that creates customized prescription medications to meet individual patients' needs, today announced it has achieved accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a service of Accreditation...

2014-09-05 16:20:40

ENGLEWOOD, Colo., Sept. 5, 2014 /PRNewswire/ -- Mayo Aviation, Inc., a premier provider of aircraft management services and private jet charters, is proud to announce its corporate sponsorship of the Flight to Luxury event, with proceeds benefiting Boys & Girls Clubs of Metro Denver. The event, presented by Cuvee Escapes, will be held on September 12, 2014 and will showcase custom-couture private villas by Cuvee, elite private jets, exotic cars, and live entertainment. Mayo...

2014-09-02 08:29:23

ENGLEWOOD, Colo., Sept. 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on the phase III, multicenter, double-blind STEP study of Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO The STEP study enrolled 538 patients, 269 patients received Ampion(TM) and 269 patients received saline vehicle control. There were two primary endpoints: 1. Efficacy in reducing pain, as measured by the WOMAC A pain...

2014-08-25 08:27:22

ENGLEWOOD, Colo., Aug. 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study and clarify its plan for moving forward with Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Letter to Ampio Shareholders from Michael Macaluso, Chairman & CEO and David Bar-Or, MD, Chief Scientific Officer The STEP study of Ampion(TM)...

2014-08-21 08:28:33

ENGLEWOOD, Colo., Aug. 21, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a delay in the data analysis of the STEP Study due to the discovery by the independent Clinical Research Organization (CRO) that the study drug (both Ampion(TM) and the placebo) were, during shipment to the clinical sites, exposed to lower temperatures than permitted by the drug specifications. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Michael Macaluso, Ampio's...

2014-08-20 08:27:41

ENGLEWOOD, Colo., Aug. 20, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that in response to requests from patients and physicians, the company has performed an analysis of the available data from both portions of the study. On October 7, 2013, following an IDRC determination "that there was a treatment dosage (of Optina(TM)) that was demonstrating a potentially beneficial anatomic effect." The company initiated an open label extension study using the...

2014-08-18 08:28:51

ENGLEWOOD, Colo., Aug. 18, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 6 weeks results of the open label portion of the multiple injections of Ampion(TM) into the knees of patients (n=7) with osteoarthritis (OA). http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Vaughan Clift, MD, Ampio's Chief Regulatory Officer explained: "This first part of the multiple injection study involved patients receiving a series of three 4ml injections...

2014-08-11 08:28:51

With CE mark in place and FDA-directed studies underway in US, company accelerates market development efforts in US, Canada, Israel, and multiple countries in Europe ENGLEWOOD, Colo., Aug. 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis Diagnostics has expanded its academic and pharmaceutical research network to over 25 sites around the world. To date the company has initiated over 17 scientific and clinical research...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.